Promising investigational treatment, commonly known as Retatrutide is for metabolic dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease. MASLD has become increasingly prevalent due to rising obesity rates, affecting 38% of the global population by 2019. Retatrutide is targeting the GIP, GLP-1, and glucagon receptors, has shown potential in reducing liver fat and improving metabolic markers. In a phase 2 study liver fat content was significantly reduced, and weight loss was induced in participants, demonstrating its therapeutic promise.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For more details consult with your doctor or healthcare professional.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.
Home
